- Scinai Immunotherapeutics Ltd. has submitted a revised application for €12 million in non-dilutive funding under the EU FENG SMART Path program to support development of PC111, a monoclonal antibody targeting sFasL.
- The company executed a Second Amendment to its Binding Option Agreement for the acquisition of PinCell S.r.l., extending option deadlines to August 31 and September 30, 2026.
Scinai Immunotherapeutics Ltd. announced the execution of a Second Amendment to its Binding Option Agreement for the acquisition of PinCell S.r.l., alongside the submission of a revised funding application under the European Funds for the Modern Economy (FENG) SMART Path program. The application seeks €12 million in non-dilutive, non-repayable funding to support a €15 million integrated R&D program for PC111.
PC111 is a fully human monoclonal antibody targeting soluble Fas Ligand (sFasL) for the treatment of pemphigus vulgaris (PV) and Stevens–Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN). The requested grant would represent 80% project co-financing. The company expects a funding decision within three to four months following submission.
The Second Amendment aligns the option timeline for the PinCell acquisition with the grant evaluation process. Under the revised terms, the deadline for fulfillment of option conditions extends to August 31, 2026, with the option exercise period extended to September 30, 2026.
According to the company, the revised SMART Path submission incorporates structural enhancements to project design and translational scope. The updated framework advances PC111 through milestone-driven development culminating in integrated non-clinical and First-in-Human datasets intended to support progression decisions. If awarded, the €12 million grant would enable Scinai to complete early clinical development and human proof of concept while preserving balance sheet flexibility.
“The revised submission reflects a structurally strengthened innovation framework and a clearly defined translational pathway through human proof of concept. Securing substantial non-dilutive funding at this stage would meaningfully de-risk the PC111 program while maintaining disciplined capital allocation and preserving strategic flexibility.”
Amir Reichman, Chief Executive Officer of Scinai
